The primary objective of the study is to determine the effects of KAI-9531 subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Dose 3 and 4 versus Placebo: Percent Change From Baseline in Body Weight at Week 76
Timeframe: Baseline, Week 76